Inverness Medical Innovations (IMA) Raises Bid for Biosite (BSTE) to $92.50
Inverness Medical Innovations (Amex: IMA) raises bid for Biosite (Nasdaq: BSTE) from $90 to $92.50 per share.
Biosite is currently in a merger agreement with Bechman Coulter (NYSE: BEC) to be acquired for $90 per share.
Inverness CEO Ron Zwanziger said they, "are confident that Biosite will respond favorably to our new offer and once again deem it a Superior Proposal."
Biosite is currently in a merger agreement with Bechman Coulter (NYSE: BEC) to be acquired for $90 per share.
Inverness CEO Ron Zwanziger said they, "are confident that Biosite will respond favorably to our new offer and once again deem it a Superior Proposal."
You May Also Be Interested In
- UPDATE: SAP's (SAP) America Unit to Buy Ariba (ARBA) for $45/Share
- BofA (BAC), Barclays (BCS) to Sell Remaining Archstone Interest in $1.58B Deal to Lehman Bros.
- Rhoen-Klinkum to recommend Fresenius (FMS) takeover offer -Bloomberg
Create E-mail Alert Related Categories
Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
